Fact CheckerSign in

NCT06384729Completed

Effectiveness of the EXOPULSE Mollii Ⓡ Suit in Patients With Multiple Sclerosis

Effectiveness of the EXOPULSE Mollii Ⓡ Suit in Patients With Multiple Sclerosis: Randomized Clinical Trial

Source: ClinicalTrials.gov · Last updated 17 Jun 2025

Brief summary (registry, in English)

Abstract: Background: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system with unknown etiology, causing a variety of symptoms including impaired balance, coordination, and walking difficulties. The Exopulse Mollii Ⓡ suit is an innovative approach for non-invasive, self-administered electrical stimulation designed to alleviate spasticity and improve motor function in various neurological conditions. Objective: To determine the effectiveness of the Exopulse Mollii Ⓡ suit in improving motor control in patients with MS. Methods: A randomized, double-blind clinical trial will be conducted, recruiting patients diagnosed with MS , aged 18 or above, with a Functional Ambulation Category (FAC) score between 2 and 4. Patients will be randomly assigned to two groups receiving either inactive or active Exopulse Mollii Ⓡ treatment for 60 minutes, three times a week, for three weeks. Outcome measures include pain, balance, gait speed, risk of falls, perception of walking difficulties, and quality of life assessed using validated scales. Statistical analysis will be performed using SPSS v.29.0.0.0. Results: Data on age, sex, weight, and MS-related factors will be collected at baseline. Primary outcomes include changes in pain, balance, and gait speed, while secondary outcomes encompass risk of falls, perception of walking difficulties, and quality of life. Analysis will compare mean differences between groups using appropriate statistical tests. Conclusion: This study aims to evaluate the efficacy of the Exopulse Mollii Ⓡ suit in enhancing motor function in MS patients. Findings may contribute to the development of novel therapeutic strategies for managing MS-related symptoms and improving patients' quality of life.

Status (registry)
Completed
Study type
Interventional
Enrollment
12 (actual)
First submitted
8 Apr 2024
Start date
1 Apr 2024
Primary completion date
1 May 2024
Lead sponsor
Universidad Europea de Madrid
NCT number
NCT06384729

What you commit to

  • Study type: Interventional
  • Participants enrolled: 12
  • From 1 Apr 2024 to the primary completion date, 1 May 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Pregnancy.
    • Having an intrathecal baclofen pump.
    • Having received botulinum toxin injections in the last 3 months.
    • Wearing electronic or magnetic medical devices (pacemakers, shunts, etc.) that may be affected by magnets.
    • BMI \> 35.

Who the study is looking for

  • • Diagnosis of Multiple Sclerosis as confirmed by a physician using McDonald's criteria.
    • Age over 18 years.
    • Ability to comprehend verbal commands.
    • Scoring between 2 and 4 on the Functional Ambulation Category (FAC).

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Cecilia Estrada Barranco
Coordinator of this site? Confirm its status
Villaviciosa de OdónSpainUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.